Clinical trials: Gastric Cancer Stage II
Stage I Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma
Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer
The therapy of photofrin PDT was effective in improving life quality of patients with advanced esophageal and/or gastric cardiac cancer and the time optimizing for employing laser irradiation was of great importance.The purpose…
- Conditions
- Stage I Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage I Esophageal Squamous Cell Carcinoma
- Trial name
- NCT02628665
- Testing
- photosensitizer(photofrin), 630 nm laser irradiation (DIOMED)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Stomach Neoplasms, Gastric Cancer
Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer
The aim of this study is to test the efficacy and safety of immunotherapy plus chemotherapy on people with a relatively rare type of gastric cancer.
- Conditions
- Stomach Neoplasms, Gastric Cancer, Linitis Plastica of Stomach
- Trial name
- Neo-ICEBOAT (NCT06451211)
- Testing
- Tislelizumab, Oxaliplatin, S-1
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Sun Yat-sen University
Gastric Cancer
Study of Weekly DCF to Treat Advanced Gastric Cancer
The purpose of this study is to evaluate the efficacy of weekly docetaxol combined with cisplatin and 5-Fu in patients with AGC.
- Trial name
- NCT00568971
- Testing
- Docetaxel, Cisplatin, 5-Fu
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Esophageal Cancer, Gastric Cancer
Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00397904
- Testing
- cetuximab, cisplatin, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastric Adenocarcinoma
PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER
This is a Phase II treatment study analyzing the role of preoperative chemotherapy, preoperative laparoscopic HIPEC, and gastrectomy with CRS/HIPEC in gastric adenocarcinoma patients with cytology-positive only carcinomatosis…
- Trial name
- NCT07178808
- Testing
- Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Banner Health
Gastric Cancer
FOLFOX Followed by FOLFIRI or Reverse Sequence Treatment in Advanced Gastric Cancer (AGC)
FOLFOX* followed by FOLFIRI** or reverse sequence treatment regimen have been used as a standard treatment modality in metastatic colorectal cancer.Oxaliplatin and Irinotecan were used for advanced gastric cancer also.
- Trial name
- NCT01138904
- Testing
- irinotecan, oxaliplatin, oxaliplatin, irinotecan
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Dong-A University Hospital
Gastric Cancer, AFP
PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma
The purpose of this study is to evaluate the efficacy and safety of PD-1 antibody combined with apatinib mesylate in patients with unresectable, local advanced recurrent or metastatic serum AFP-elevated gastric adenocarcinoma…
- Trial name
- NCT04006821
- Testing
- PD-1 antibody, Apatinib mesylate
- Where
- China
- Volunteers
- 30 people
- Sponsor
- China Medical University, China
Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC)
A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
This study is a multicenter, open-label, phase II clinical trial evaluating the combination of SSGJ-706 with standard therapy for advanced gastrointestinal tumors.
- Conditions
- Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Oesophageal Cancer
- Trial name
- NCT07233850
- Testing
- SSGJ-706+XELOX, SSGJ-706+Bevacizumab+XELOX, SSGJ-706+AG
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Stomach Neoplasms
Study of Continuous or Intermittent S-1 Combined With Oxaliplatin in Recurrent or Metastatic Gastric Carcinoma
Randomized phase II study designed to evaluate the efficacy and safety of continuous S-1 plus oxaliplatin versus intermittent S-1 plus oxaliplatin as first-line therapy in patients with recurrent and/or metastastic gastric…
- Trial name
- NCT00515190
- Testing
- S-1,oxaliplatin
- Where
- South Korea
- Volunteers
- 198 people
- Sponsor
- National Cancer Center, Korea
Gastric Cancer
Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer
This open-label, single-arm, multicenter, Phase 2 trial will treat at least 40 participants with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction (GEJ) who have not previously received…
- Trial name
- NCT01388790
- Testing
- Cetuximab, Cisplatin, S-1
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Locally Advanced or Metastatic Solid Tumors, PTEN Loss or Low Expression
A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression
This is a single-arm, open-label, multicenter, Phase Ib/II clinical trial of CVL237 tablets in combination with serplulimab injection for the treatment of advanced solid tumors with PTEN loss or low expression
- Trial name
- NCT07446049
- Testing
- CVL237 tablets
- Volunteers
- 180 people
- Sponsor
- Convalife (Shanghai) Co., Ltd.
Neuroendocrine Tumor G1 (NET G1)/Carcinoid, Neuroendocrine Tumor Grade 2
Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases
An international multi-centre, open, randomised, parallel-group phase II study comparing adjuvant treatment with 177Lu-DOTATATE to best supportive care in patients after complete surgical removal of neuroendocrine liver…
- Conditions
- Neuroendocrine Tumor G1 (NET G1)/Carcinoid, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors, Liver Metastases
- Trial name
- NELMAS (NCT05987176)
- Testing
- Lutathera
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Imperial College London
Gastric Cancer
Gastric Cancer RAD001 Study
The purpose of this study is to determine dose limiting toxicities (DLT) and maximum tolerated dose (MTD) of RAD001, as well as to assess tumor response and overall survival.
- Trial name
- NCT01514110
- Testing
- RAD001
- Where
- Hong Kong
- Volunteers
- 35 people
- Sponsor
- Chinese University of Hong Kong
HER2-positive Gastric Cancer
RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer
A single-arm, single-center phase II trial study to assess the efficacy and safety of disitamab vedotin plus cadonilimab as first-line therapy for HER2-overexpressing advanced stomach carcinoma
- Trial name
- NCT06492317
- Testing
- Disitamab Vedotin, Cadonilimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma
Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin or carboplatin and etoposide in treating patients with neuroendocrine carcinoma of the…
- Conditions
- Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma
- Trial name
- NCT02595424
- Testing
- Capecitabine, Carboplatin, Cisplatin
- Where
- 673 sites in United States
- Volunteers
- 67 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Metastatic Colorectal Cancer, Triple Negative Breast Cancer
Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors
To determine the efficacy (as measured by overall tumour response rate) of the combination of durvalumab and tremelimumab when given to previously treated patients with solid tumors harboring a high mutational load.
- Conditions
- Metastatic Colorectal Cancer, Triple Negative Breast Cancer, Prostate Adenocarcinoma, Stomach Adenocarcinoma
- Trial name
- MATILDA (NCT03982173)
- Testing
- Tremelimumab, Durvalumab
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Stomach Neoplasms
Phase II Study of Perioperative S-1 Plus Docetaxel in Patients With Localized Advanced Gastric Cancer
This study is an open-label, single center, and a single arm phase II study to evaluate the clinical response and safety of perioperative S-1 plus docetaxel.
- Trial name
- NCT00587145
- Testing
- S-1,Docetaxel
- Where
- South Korea
- Volunteers
- 44 people
- Sponsor
- National Cancer Center, Korea
Recurrent Gastric Cancer
A Study of Genomic-guided 'Standard-of-care' Chemotherapy for in Advanced Gastric Cancer Patients
This is an open, non-randomized, multicenter Phase II study evaluating cisplatin plus TS-1 or oxaliplatin plus TS-1 as first-line therapy in predicted 'responder' to platinum and fluoropyrimidine.
- Trial name
- 3G (NCT01100801)
- Testing
- TS-1 with cisplatin, TS-1 with oxaliplatin
- Where
- Singapore
- Volunteers
- 90 people
- Sponsor
- National University Hospital, Singapore
Gastric Cancer, Gastroesophageal Junction (GEJ) Adenocarcinoma
Becotatugvedotin Plus Pucotenlimab in EGFR-Positive Advanced Gastric/GEJ Adenocarcinoma
Advanced gastric cancer (AGC) and gastroesophageal junction (GEJ) adenocarcinoma remain associated with poor prognosis after failure of first-line systemic therapy.
- Conditions
- Gastric Cancer, Gastroesophageal Junction (GEJ) Adenocarcinoma, Becotatug Vedotin, Pucotenlimab
- Trial name
- NCT07692334
- Testing
- Becotatug Vedotin (MRG003), Pucotenlimab
- Volunteers
- 28 people
- Sponsor
- West China Second University Hospital
Stomach Neoplasms
Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer
The purpose of this study is to explore the safety and feasibility of the Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for patients with locally advanced upper third gastric adenocarcinoma（cT2-4a, N-/+, M0）.
- Trial name
- CLASS-04 (NCT02845986)
- Testing
- Laparoscopic Spleen-Preserving No.10 Lymph Node Dissections, oxaliplatin
- Where
- 20 sites in China
- Volunteers
- 251 people
- Sponsor
- Fujian Medical University